-
Optimizing medical and lifestyle change therapy rather than performing PCI is appropriate as the initial management strategy for most patients with known CAD who do not have unstable or disabling symptoms.
-
There are no disease-modifying pharmacotherapies for COPD. That is, although bronchodilators, anticholinergic agents, and inhaled corticosteroids improve FEV1 and reduce symptoms, decline in pulmonary function continues unabated and lung function returns promptly to pretreatment status once medication is stopped.
-
A randomized controlled trial in the Netherlands showed that oral prednisolone and naproxen were equivalent in the treatment of acute gout with no difference in side effects.
-
Strategies to determine treatment of acute coronary syndromes need to take gender into account.
-
Using blood pressure, BUN, serum sodium, and presence of peripheral arterial disease as predictors of mortality in heart failure patients, 67% who had 3 or more factors died within 6 months and would qualify for the Medicare hospice benefit.
-
Valproic acid and phenytoin were equally effective in the treatment of acute repetitive seizures and status epilepticus.
-
There are no randomized controlled treatment trials of cervical artery dissection, and the most effective therapy is uncertain.
-
5-α reductase inhibitors and hip fracture in men; the effects of drug-reimbursement policy on outcomes; new guidelines for type 2 diabetes; beta-blocker-associated brady-cardia is linked to CVD events; FDA Updates.
-
-
Anxiety is a common but underrecognized symptom of Parkinson's disease, for which there are a number of suggested but no recommended rating scales.
